



ESOU18

15th Meeting of the EAU Section of
Oncological Urology

26-28 January 2018, Amsterdam, The Netherlands

www.esou18.org

esou

EAU
European
Association
of Urology

Tentative Scientific Programme

Friday, 26 January 2018

08.30 – 08.40 Welcome

M. Brausi, Modena (IT)

08.40 – 09.00 Opening address

The future of urology: The EAU perspective

09.00 – 13.10 Prostate Cancer I: Diagnosis, pathology, screening, active surveillance

Chairs: M. Brausi, Modena (IT)

09.00 – 09.15 Reflex testing with serum, urine and tissue biomarkers: Which, when and how viable?

09.15 – 09.20 Questions

09.20 – 09.35 Genetic testing in inherited prostate cancer

09.35 – 09.40 Questions

09.40 – 09.55 Morphologic basis of mpMRI prostate cancer evaluation

09.55 – 11.30 MRI imaging targeted prostate biopsy: Comparing 3 different techniques. Is there really a difference in results?

09.55 – 10.05 Fusion biopsy (+ video)

10.05 – 10.15 In-bore biopsy (+ video)

10.15 – 10.25 Cognitive biopsy

10.25 – 10.45	Discussion with clinical cases
10.45 – 11.00	MRI in men on active surveillance for prostate cancer: The PRECISE recommendations
11.00 – 11.15	Biopsy or monitoring patients with negative MRI
11.15 – 11.30	Discussion
11.30 – 12.00	Break
12.00 – 12.15	How have recommendations against prostate cancer screening impacted the incidence and mortality of prostate cancer in the US
12.15 – 12.25	Discussion
12.25 – 13.10	ROUND TABLE: Treatment modalities for intermediate risk prostate cancer: surgery vs hypofractionation RT vs focal therapy vs active surveillance Chairs:
12.25 – 12.33	Surgery
12.33 – 12.41	RT
12.41 – 12.49	Focal therapy
12.49 – 12.57	Active surveillance
12.57 – 13.10	Discussion
13.10 – 14.00	Lunch
14.00 – 15.05	Renal cancer I: Localised Alternative approaches for characterization of renal tumors Chairs:
14.00 – 14.10	MRI
14.10 – 14.20	Conventional and optical renal mass biopsy

14.20 - 14.30	Liquid biopsy
14.30 - 14.45	Discussion
14.45 - 15.00	The WHO ISUP classification of renal tumors: What has changed?
15.00 - 15.05	Discussion
15.05 - 15.30	Treatment of renal cancer in the elderly (>75years) Chairs:
15.05 - 15.30	Is partial nephrectomy always the best choice for T1b tumors?
15.05 - 15.15	Yes
15.15 - 15.25	No
15.25 - 15.30	Discussion
15.30 - 16.00	DEBATE: Clamped vs. unclamped partial nephrectomy (Open, Lap. Robotic)
15.30 - 15.40	Clamped (+ video)
15.40 - 15.50	Unclamped (+ video)
15.50 - 16.00	Discussion
16.00 - 16.30	Panel discussion of clinical cases: Localised RCC Chair: Panelists:
16.30 - 16.45	Surveillance after nephrectomy: On the way towards evidence based protocols
16.45 - 17.15	Break
17.15 - 17.45	Controversial subjects on bladder cancer The role of extended lymphadenectomy for bladder cancer Chairs:
17.15 - 17.25	The American perspective

17.25 - 17.35	European perspective
17.35 - 17.45	Discussion
17.45 -18.10	Robotic assisted radical cystectomy: Always the right urinary diversion?
17.45 - 17.55	No
17.55 - 18.05	Yes
18.05 - 18.10	Discussion
18.10 - 18.50	Is there a role for local treatment in metastatic disease?
18.10 - 18.20	The urologist perspective
18.20 - 18.30	The medical oncologist perspective
18.30 - 18.40	The radiation oncologist perspective
18.40 - 18.50	Discussion

Saturday, 27 January 2018

08.30 – 10.20 Prostate cancer II: Locally advanced

Chairs:

08.30 – 08.45 Tools for detection of node metastasis: PSMA guided surgery

08.45 – 09.40 Management of loco-regional recurrence after definitive treatment

08.45 – 09.00 Cryoablation (+ video)

09.00 – 09.15 Salvage radiation therapy

09.15 – 09.30 Salvage radical prostatectomy – Robotic (+ video)

09.30 – 09.40 Discussion

09.40 – 10.20 DEBATE: Reappraisal of neoadjuvant therapy for high and very high-risk PCA

09.40 – 09.55 Yes - it does make sense

09.55 – 10.10 No - it is useless

10.10 – 10.20 Discussion

10.20 – 11.00 Is lymph node dissection necessary in prostate cancer?

10.20 – 10.35 The American view

10.35 – 10.50 The European view

10.50 – 11.00 Discussion

11.00 – 11.20 Break

11.20 – 12.20 Testis and penile cancer
Reducing treatment aggressiveness without impairing outcomes

11.20 – 11.40 Conservative surgery for penile cancer: Indications and techniques (+ video)

11.40 – 11.45 Discussion

11.45 - 11.55	From radical inguinal lymph node dissection to sentinel lymph node dissection for penile cancer
11.55 - 12.00	Discussion
12.00 - 12.10	Evolution of surgical techniques in testis cancer (+ video)
12.10 - 12.20	Discussion
12.20 - 14.00	Urothelial cancer II: Non muscle invasive bladder cancer Chairs:
12.20 - 12.30	New techniques for bladder tumor resection: are they better than conventional TURBT?
12.30 - 12.35	Discussion
12.35 - 12 45	Complications of TURBT
12.45 - 12.50	Discussion
12.50 - 13.00	Socio-economic impact of BCG shortage
13.00 - 13.05	Discussion
13.05 - 13.15	Genomic classification of non muscle invasive bladder tumours
13.15 - 14.00	Panel discussion – Second opinion in difficult clinical cases Chair: Panelists:
14.30 - 16.45	STEPS (Session To Evaluate ProgresS) programme Closed programme: participation by invitation only Led by Prof. M. Brausi, Modena (IT)
14.30 - 17.00	ESU Course on renal cancer Chair:

Sunday, 28 January 2018

09.00 – 10.30 Prostate cancer III: Advanced and metastatic disease

Chairs:

09.00 – 09.15 Open vs robotic surgery for locally advanced prostate cancer: Oncological and functional outcomes

09.15 – 09.20 Discussion

09.20 – 09.45 New trends for treatment of oligo metastatic prostate cancer

09.20 – 09.30 Radical prostatectomy

09.30 – 09.40 Radiotherapy

09.40 – 09.50 Chemo-hormone therapy

09.50 – 10.00 Discussion

10.00 – 10.30 Salvage LND after radical prostatectomy for PSA recurrence: An up-date

10.00 – 10.10 Robotic (Video)

10.10 – 10.20 Open (Video)

10.20 – 10.30 Discussion

10.30 – 11.00 Break

11.00 – 12.00 The best paper in uro-oncology 2017

Chairs:

11.00 – 11.15 Prostate cancer

11.15 – 11.30 Renal cancer

11.30 – 11.45	Urothelial cancer
11.45 – 12.00	Testis and penile cancer
12.00 – 13.30	Renal cancer II: Locally advanced and metastatic Chairs:
12.00 – 12.15	The role of neoadjuvant and adjuvant therapy in kidney cancer
12.15 – 12.20	Discussion
12.20 – 12.35	Cytoreductive nephrectomy for metastatic RCC in the targeted therapy era
12.35 – 12.40	Discussion
12.40 – 12.55	The revival of immunotherapy in RCC and novel clinical trials
12.55 – 13.00	Discussion
13.00 – 13.30	Clinical case discussion Chair: Panelists:
13.30 – 13.35	Closing remarks M. Brausi, Modena (IT)